dysisSmart Colposcopy
Transforming Colposcopy
Map. Track. Zoom.
Why should colposcopy change?• Colposcopy is subjective and variable, which can lead to missed disease1
• More sensitive screening tests detect smaller high-grade lesions2
• Numerous studies report improvement in biopsy is needed3
0%
20%
40%
60%
80%
100%
ColposcopyCervical Screening
1970-1990Pap smear
1990Liquid-based
cytology
2000HPV testing
& typing
90%
70%
50%
30%
10%
1970 - PresentColposcopySensitivity
More biopsies canimprove sensitivity,
but they are costly andpainful to patients
TEST
ING
SEN
SITI
VITY
Colposcopy hasn’t changed in decades
Is the current way of documenting good enough?
Precisionin biopsy, treatment and patient management
• Reduced risk of missing high grade disease4
• Reduced risk of unnecessary treatment
• Added reassurance in biopsy and treatment decisions
DocumentationSMARTtrack for conservative management of young women
• Effectively monitor cervical changes over time
• Dynamic playback for post-exam review
• High-resolution images and video
• EMR-compatible
Reassurance for you and your patient
• Increased patient understanding
• Increased patient compliance
• Reduced patient anxiety4
• Patients and providers prefer DYSIS over conventional colposcopy5
DYSIS Smart ColposcopyWith cervical mapping for precise assessment, biopsy and treatment
Clinician touchscreen tablet• Intuitive HD touchscreen
• Clinically proven DYSISmap algorithm
• Biopsy markers document and guide biopsy
• Comprehensive documentation and reports
• Magnification, green and high-contrast filters
DYSIS Ultra Colposcope
Imaging head• Automated acetic acid delivery system
• Collects dynamic high resolution images and video for playback and later review
• Polarization reduces glare and can be turned off during treatment for 3-D effect
• White light LED adjustable brightness
On-board patient database• Automatic image and documentation
storage for longitudinal tracking
• Industry standard EMR compatibility
• Expandable storage capacity
Teaching monitor• Adjustable positioning for patient education
• Playback during live viewing for more effective residency education
Ask about the DYSIS Touch ColposcopeSmart innovation for small practices
Imaging head• Automated acetic acid delivery system
• Collects dynamic high resolution images and video for playback and later review
• Polarization reduces glare and can be turned off during treatment for 3-D effect
• White light LED adjustable brightness
On-board patient database• Automatic image and documentation
storage for longitudinal tracking
• Industry standard EMR compatibility
• Expandable storage capacity
Teaching monitor• Adjustable positioning for patient education
• Playback during live viewing for more effective residency education
Clinical Evidence
0%
20%
40%
60%
80%
100%
54%
85% 88%
97%
HPV 16+ Referrals10
n=42
LG & HGReferrals9
n=183
Low-Grade Referrals8
n=166
ASCUSALTSTrial7
LSILALTSTrial6
44%
55% 53%56%
Conventional Colposcopy + DYSISmap
Conventional ColposcopySensitivity of Conventional and DYSIS Colposcopy to CIN2+
U.S. IMPROVE-COLPO Study11
“There is no doubt that we are more accurate with the DYSIS colposcope. There have definitely been times that the DYSISmap has helped me to pick up areas of dysplasia that I would not have otherwise biopsied. With the DYSIS Colposcope, not only has our detection rate increased, but the level of education and understanding for our patients has significantly improved.
Andrew Shimer, MD, FACOGCraig Ranch OB/GYN, McKinney, TX
“I’m impressed by the DYSIS Colposcope. Its ability to help me to select biopsy sites has resulted in me finding an increased number of significant pathologies.”
John Patterson, MD, FACOG Wheaton Franciscan Healthcare, Racine, WI
DYSIS-guided biopsies increased the number of women detected with CIN2+ (n=194)12
Increased detection of CIN2+ in ASC-US/HPV+ women in DYSIS arm vs.
conventional colposcopy arm (n=2536)13
0%
2%
4%
6%
8%
10%
12%
Efficiency of biopsyto find CIN2+ (PPV)
CIN2+ detection
0
5
10
15
20
25
30
CIN2+ after DYSISmap
CIN2+ before DYSISmap
Colposcopic impression
+36.8%p=0.015
+42.9%p=0.013
+35.4%p=0.017
dysisSmart Colposcopy
Call [email protected]
SMALLDESIGN SMART INNOVATION
1Jeronimo and Schiffman, AJOG 2006;195:349-53; 2Sherman et al, Cancer Epidemiology Biomarkers & Prevention. 2003;12:372-9; 3Massad et al, Gynecologic Oncology 1996;60:400-3. Huh et al, Obstetrics & Gynecology 2014;124:670-8. Stoler et al, International Journal of Cancer 2011;128:1354-62; 4Louwers J, et al, BJOG 2011 Feb; 118(3):309-18; 5Global Patient Experience Survey, data on file. DYSIS Provider Survey, September 2016 data on file; 6ALTS Group, AJOG 2003;188:1393-400; 7ALTS Group, AJOG 2003;188:1383-92; 8Louwers, JA, et al, Gynecologic Oncology 2015; 139:452-457; 9Louwers J, et al, BJOG 2011 Feb; 118(3):309-18; 10Zaal A, et al, BJOG 2012 Apr; 119(5):537-44; 11Clinical Trials.gov NCT02185599; 12Presented at ASCCP 2016 meeting; Journal of the Lower Genital Tract Disease 2016:20(2); 13Presented at the ASCCP/IFCPC 2017 meeting.
In 2010 the UK Regulator, NICE (National Institute of Health and Care Excellence) launched an investigation into the clinical efficacy and cost efficiency of various new technologies in the cervical screening category. The review involved an independent analysis of the published clinical trials followed by a detailed review of the health economics. DYSIS was the only technology deemed to be both clinically effective and cost saving. The report, containing the recommendation from NICE, was published in 2012.
In March 2016, NHSCSP published the 3rd edition of Publication no.20, Colposcopy and Programme Management. Publication 20, which advises on the latest advancements in cervical screening, has recognised the DYSIS Colposcope for its clinical and financial benefits.
0354-01248© 2017 DYSIS Medical